Understanding the Time Needed to Link to Care and Start ART in Seven HPTN 071 (PopART) Study Communities in Zambia and South Africa.
Adolescent
Adult
Aged
Anti-HIV Agents
/ administration & dosage
Antiretroviral Therapy, Highly Active
/ methods
CD4 Lymphocyte Count
Continuity of Patient Care
Female
HIV Infections
/ diagnosis
Health Services Accessibility
Healthcare Disparities
Humans
Male
Middle Aged
Patient Acceptance of Health Care
Prevalence
Referral and Consultation
South Africa
/ epidemiology
Time-to-Treatment
Young Adult
Zambia
/ epidemiology
Access
Anti-retroviral treatment
HIV
Linkage to care and ART
Southern Africa
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
pubmed:
12
11
2018
medline:
19
6
2019
entrez:
12
11
2018
Statut:
ppublish
Résumé
To achieve UNAIDS 90:90:90 targets at population-level, knowledge of HIV status must be followed by timely linkage to care, initiation and maintenance of antiretroviral therapy (ART) for all people living with HIV (PLHIV). Interpreting quantitative patterns using qualitative data, we investigate time taken to link to care and initiate ART amongst individuals aware of their HIV-status in high HIV-prevalence urban communities in the HPTN 071 (PopART) study, a community-randomised trial of a combination HIV prevention package, including universal testing and treatment, in 21 communities in Zambia and South Africa. Data are drawn from the seven intervention communities where immediate ART irrespective if CD4 count was offered from the trial-start in 2014. Median time from HIV-diagnosis to ART initiation reduced after 2 years of delivering the intervention from 10 to 6 months in both countries but varied by gender and community of residence. Social and health system realities impact decisions made by PLHIV about ART initiation.
Identifiants
pubmed: 30415432
doi: 10.1007/s10461-018-2335-7
pii: 10.1007/s10461-018-2335-7
pmc: PMC6458981
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
929-946Subventions
Organisme : Medical Research Council
ID : MR/K012126/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U01 AI068617
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068617
Pays : United States
Références
N Engl J Med. 2000 Mar 30;342(13):921-9
pubmed: 10738050
Lancet. 2009 Jan 3;373(9657):48-57
pubmed: 19038438
PLoS Med. 2011 Jul;8(7):e1001056
pubmed: 21811403
PLoS One. 2011;6(11):e27917
pubmed: 22114727
Curr Opin HIV AIDS. 2012 Mar;7(2):99-105
pubmed: 22227585
AIDS. 2012 Sep 10;26(14):1735-8
pubmed: 22614888
PLoS Med. 2012;9(12):e1001351
pubmed: 23226107
PLoS Med. 2013;10(9):e1001510
pubmed: 24137103
AIDS. 2013 Aug 24;27(13):2155-60
pubmed: 24384592
AIDS. 2014 Jan 14;28(2):227-33
pubmed: 24413310
Clin Infect Dis. 2014 Apr;58(7):1012-4
pubmed: 24429442
Trials. 2014 Feb 13;15:57
pubmed: 24524229
Clin Infect Dis. 2014 Jul;59 Suppl 1:S28-31
pubmed: 24926029
Clin Infect Dis. 2014 Jul;59 Suppl 1:S32-4
pubmed: 24926031
AIDS Behav. 2015 Apr;19(4):704-14
pubmed: 25304330
Trop Med Int Health. 2015 Apr;20(4):430-47
pubmed: 25583302
AIDS Care. 2015;27(6):753-7
pubmed: 25650545
AIDS Behav. 2015 Feb;19(2):322-9
pubmed: 25677128
J Int AIDS Soc. 2015 Mar 02;18:19395
pubmed: 25735869
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
Nature. 2015 Dec 3;528(7580):S68-76
pubmed: 26633768
BMC Public Health. 2016 Jan 28;16:87
pubmed: 26823077
BMC Med. 2016 Feb 19;14:34
pubmed: 26891969
Lancet HIV. 2016 Mar;3(3):e111-9
pubmed: 26939734
Malawi Med J. 2015 Dec;27(4):125-7
pubmed: 26952140
J Int AIDS Soc. 2016 Mar 11;19(1):20672
pubmed: 26976377
Trop Med Int Health. 2016 Jun;21(6):743-9
pubmed: 27097834
PLoS Med. 2016 May 10;13(5):e1002015
pubmed: 27163694
J Int AIDS Soc. 2016 Jun 01;19(1):20913
pubmed: 27258430
Health Policy Plan. 2016 Dec;31(10):1342-1354
pubmed: 27375126
Curr HIV/AIDS Rep. 2016 Aug;13(4):194-201
pubmed: 27405816
AIDS Care. 2016;28 Suppl 3:33-8
pubmed: 27421050
AIDS Care. 2016;28 Suppl 3:99-107
pubmed: 27421057
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
PLoS Med. 2016 Aug 09;13(8):e1002107
pubmed: 27504637
AIDS Patient Care STDS. 2016 Sep;30(9):425-34
pubmed: 27610464
J Int AIDS Soc. 2016 Dec 01;19(1):21484
pubmed: 27914186
PLoS Med. 2017 Apr 11;14(4):e1002268
pubmed: 28399160
PLoS Med. 2017 May 2;14(5):e1002292
pubmed: 28464041
AIDS. 2017 Jul 17;31(11):1555-1564
pubmed: 28471766
Lancet HIV. 2017 Aug;4(8):e324-e326
pubmed: 28501496
AIDS. 2017 Jun 19;31(10):1489-1493
pubmed: 28574966
AIDS Behav. 2018 Mar;22(3):722-732
pubmed: 28643242
Sex Transm Infect. 2017 Jul;93(Suppl 3):
pubmed: 28736390
PLoS Med. 2017 Jul 25;14(7):e1002357
pubmed: 28742880
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21650
pubmed: 28770594
J Int AIDS Soc. 2017 Aug 29;20(Suppl 6):21780
pubmed: 28872272
AIDS Res Hum Retroviruses. 2018 Mar;34(3):254-260
pubmed: 28969432
AIDS. 2018 Jan 2;32(1):17-23
pubmed: 29112073
AIDS Behav. 2018 Mar;22(3):1053-1061
pubmed: 29127534
N Engl J Med. 2017 Nov 30;377(22):2154-2166
pubmed: 29171817
Lancet HIV. 2018 Mar;5(3):e116-e125
pubmed: 29199100
J Int AIDS Soc. 2017 Dec;20(4):
pubmed: 29251433
AIDS. 2018 Mar 27;32(6):783-793
pubmed: 29369164
JAMA. 2018 Mar 20;319(11):1103-1112
pubmed: 29509839
J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25117
pubmed: 30027643
Afr J AIDS Res. 2018 Sep;17(3):217-225
pubmed: 30132397
Health Place. 2019 Jan;55:87-99
pubmed: 30528346
Qual Health Res. 2019 Apr;29(5):700-718
pubmed: 30556470